دورية أكاديمية
أعرض في EDS

Real-Life Use of Ceftolozane/Tazobactam for the Treatment of Bloodstream Infection Due to Pseudomonas aeruginosa in Neutropenic Hematologic Patients: a Matched Control Study (ZENITH Study)

التفاصيل البيبلوغرافية
العنوان: Real-Life Use of Ceftolozane/Tazobactam for the Treatment of Bloodstream Infection Due to Pseudomonas aeruginosa in Neutropenic Hematologic Patients: a Matched Control Study (ZENITH Study)
المؤلفون: Bergas, Alba, Albasanz Puig, Adaia, Fernández-Cruz, Ana, Machado, Marina, Novo, Andrés, van Duin, David, Ruiz- Camps, Isabel, Aguilar-Company, Juan
المساهمون: Institut Català de la Salut, Bergas A Infectious Diseases Department, Bellvitge University Hospital, IDIBELL, University of Barcelona, Barcelona, Spain. Albasanz-Puig A Infectious Diseases Department, Bellvitge University Hospital, IDIBELL, University of Barcelona, Barcelona, Spain. Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain. Fernández-Cruz A Clinical Microbiology and Infectious Diseases Department, General University Hospital Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain. Infectious Disease Unit, Internal Medicine Department, Puerta de Hierro Hospital, Madrid, Spain. Machado M Clinical Microbiology and Infectious Diseases Department, General University Hospital Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain. Novo A Hematology Department, Son Espases Hospital, Mallorca, Spain. van Duin D Division of Infectious Diseases, University of North Carolina, Chapel Hill, North Carolina, USA. Ruiz-Camps I Servei de Malalties Infeccioses, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Aguilar-Company J Servei de Malalties Infeccioses, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus
المصدر: Scientia
بيانات النشر: American Society for Microbiology
سنة النشر: 2022
مصطلحات موضوعية: Hematologia oncològica, Medicaments antibacterians - Ús terapèutic, Malalties bacterianes gramnegatives - Tractament, DISEASES::Neoplasms::Neoplasms by Site::Hematologic Neoplasms, DISEASES::Bacterial Infections and Mycoses::Bacterial Infections::Gram-Negative Bacterial Infections::Pseudomonas Infections, Other subheadings::Other subheadings::Other subheadings::/drug therapy, CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Anti-Infective Agents::Anti-Bacterial Agents, Other subheadings::Other subheadings::/therapeutic use, ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias hematológicas, ENFERMEDADES::infecciones bacterianas y micosis::infecciones bacterianas::infecciones por bacterias gramnegativas::infecciones por Pseudomonas, Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia, COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antiinfecciosos::antibacterianos, Otros calificadores::Otros calificadores::/uso terapéutico
الوصف: Pseudomonas aeruginosa; Bacteremia; Neutropenia ; Pseudomonas aeruginosa; Bacteriemia; Neutropenia ; Pseudomonas aeruginosa; Bacterièmia; Neutropènia ; We sought to assess the characteristics and outcomes of neutropenic hematologic patients with Pseudomonas aeruginosa (PA) bloodstream infection (BSI) treated with ceftolozane-tazobactam (C/T). We conducted a multicenter, international, matched-cohort study of PA BSI episodes in neutropenic hematologic patients who received C/T. Controls were patients with PA BSI treated with other antibiotics. Risk factors for overall 7-day and 30-day case fatality rates were analyzed. We compared 44 cases with 88 controls. Overall, 91% of episodes were caused by multidrug-resistant (MDR) strains. An endogenous source was the most frequent BSI origin (35.6%), followed by pneumonia (25.8%). There were no significant differences in patient characteristics between groups. C/T was given empirically in 11 patients and as definitive therapy in 41 patients. Treatment with C/T was associated with less need for mechanical ventilation (13.6% versus 33.3%; P = 0.021) and reduced 7-day (6.8% versus 34.1%; P = 0.001) and 30-day (22.7% versus 48.9%; P = 0.005) mortality. In the multivariate analysis, pneumonia, profound neutropenia, and persistent BSI were independent risk factors for 30-day mortality, whereas lower mortality was found among patients treated with C/T (adjusted OR [aOR] of 0.19; confidence interval [CI] 95% of 0.07 to 0.55; P = 0.002). Therapy with C/T was associated with less need for mechanical ventilation and reduced 7-day and 30-day case fatality rates compared to alternative agents in neutropenic hematologic patients with PA BSI. IMPORTANCE Ceftolozane-tazobactam (C/T) has been shown to be a safe and effective alternative for the treatment of difficult to treat infections due to Pseudomonas aeruginosa (PA) in the general nonimmunocompromised population. However, the experience of this agent in immunosuppressed neutropenic patients is very limited. Our study is unique ...
نوع الوثيقة: article in journal/newspaper
وصف الملف: application/pdf
اللغة: English
تدمد: 2165-0497
العلاقة: Microbiology Spectrum;10(3); https://doi.org/10.1128/spectrum.02292-21Test; Bergas A, Albasanz-Puig A, Fernández-Cruz A, Machado M, Novo A, van Duin D, et al. Real-Life Use of Ceftolozane/Tazobactam for the Treatment of Bloodstream Infection Due to Pseudomonas aeruginosa in Neutropenic Hematologic Patients: a Matched Control Study (ZENITH Study). Microbiol Spectr. 2022 Jun;10(3):e0229221.; https://hdl.handle.net/11351/9557Test; 000798439700003
DOI: 10.1128/spectrum.02292-21
الإتاحة: https://doi.org/10.1128/spectrum.02292-21Test
https://hdl.handle.net/11351/9557Test
حقوق: Attribution 4.0 International ; http://creativecommons.org/licenses/by/4.0Test/ ; info:eu-repo/semantics/openAccess
رقم الانضمام: edsbas.F7DC57EB
قاعدة البيانات: BASE
الوصف
تدمد:21650497
DOI:10.1128/spectrum.02292-21